Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer umbrella study tests multiple drug combos

NCT ID NCT03337698

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested several immunotherapy-based drug combinations in people with metastatic non-small cell lung cancer. It included two groups: those who had not received prior treatment and those whose cancer had worsened after standard therapy. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444
What this could lead to
If successful, this could identify effective immunotherapy combinations for advanced lung cancer patients who have not responded to standard treatments.
What could go wrong
The trial was terminated early, so results are limited. It is an early-phase study with small groups, so any findings are preliminary and may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

314 people

The number who actually took part.

Started

Dec 2017

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General Inclusion Criteria * Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1 * Life expectancy greater than or equal to 3 months * Histologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC) * Measurable disease (at least one target lesion) * Adequate hematologic and end-organ function * Tumor accessible for biopsy * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs as outlined for each specific treatment arm * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm Inclusion Criteria for Cohort 1 * No prior systemic therapy for metastatic NSCLC * High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) or TCs \>= 50% or TC3 Inclusion Criteria for Cohort 2 \- Disease progression during or following treatment for metastatic or locally advanced, inoperable NSCLC Exclusion Criteria * Prior allogeneic stem cell or solid organ transplantation * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * History of leptomeningeal disease * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan * History of malignancy other than NSCLC within 2 years prior to screening * Active tuberculosis * Severe infection within 4 weeks prior to initiation of study treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Barts Cancer Institute

    London, E1 2AT, United Kingdom

  • Blacktown Hospital

    Blacktown, New South Wales, 2148, Australia

  • Centre Georges Francois Leclerc

    Dijon, 21079, France

  • Centre Léon Bérard

    Lyon, 69008, France

  • Chaim Sheba Medical Center

    Ramat Gan, 52620-00, Israel

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

    Las Vegas, Nevada, 89169, United States

  • Fundación Jimenez Díaz

    Madrid, 28040, Spain

  • Hopital de la Timone

    Marseille, 13005, France

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, 29010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario HM Sanchinarro-CIOCC

    Madrid, 28050, Spain

  • Hospital Universitario La Paz

    Madrid, 280146, Spain

  • Institut De Cancerologie De L'Ouest

    Saint-Herblain, 44115, France

  • Institut Régional du Cancer de Montpellier

    Montpellier, 34298, France

  • Institut Universitaire du Cancer de Toulouse-Oncopole

    Toulouse, 31100, France

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • Peter Mac Callum Cancer Center

    East Melbourne, Victoria, 3002, Australia

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center

    Haifa, 3109601, Israel

  • Royal Marsden Hospital

    Sutton, SM2 5PT, United Kingdom

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • University Hospitals Case Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)

    Songpa-gu, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.